In addition to PD-L1 status, a number of genomic and immune predictive biomarkers of response to ICI therapy in NSCLC, such as: tumour mutational burden, presence of genomic alterations in DNA damage response and other specific gene pathways, neoantigenic load, immune gene expression signatures, and immune features of the tumour microenvironment, have been investigated.12 Here, CD274 is linked to non-small cell lung carcinoma.